Date | Time | Source | Headline | Symbol | Company |
09/25/2024 | 6:45AM | PR Newswire (US) | New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis | NYSE:LLY | Eli Lilly and Co |
09/24/2024 | 6:00AM | PR Newswire (US) | Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease | NYSE:LLY | Eli Lilly and Co |
09/18/2024 | 4:19PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/17/2024 | 5:19PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/17/2024 | 5:17PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/17/2024 | 5:15PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/17/2024 | 5:11PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/17/2024 | 5:08PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/13/2024 | 4:07PM | PR Newswire (US) | FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis | NYSE:LLY | Eli Lilly and Co |
09/12/2024 | 4:16PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/12/2024 | 5:30AM | PR Newswire (US) | Lilly expands manufacturing footprint in Ireland with $1.8 billion investment | NYSE:LLY | Eli Lilly and Co |
09/10/2024 | 11:57AM | PR Newswire (US) | With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes | NYSE:LLY | Eli Lilly and Co |
09/10/2024 | 11:18AM | PR Newswire (US) | Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes | NYSE:LLY | Eli Lilly and Co |
09/10/2024 | 6:02AM | IH Market News | Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% | NYSE:LLY | Eli Lilly and Co |
09/09/2024 | 7:03AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:LLY | Eli Lilly and Co |
09/09/2024 | 6:45AM | PR Newswire (US) | Lilly appoints Lucas Montarce as executive vice president and chief financial officer | NYSE:LLY | Eli Lilly and Co |
09/05/2024 | 6:45AM | PR Newswire (US) | In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin | NYSE:LLY | Eli Lilly and Co |
09/04/2024 | 4:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
09/04/2024 | 6:00AM | PR Newswire (US) | Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries | NYSE:LLY | Eli Lilly and Co |
08/28/2024 | 4:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
08/28/2024 | 5:50AM | IH Market News | High Volatility Expected in Nvidia Report, Ambarella Soars 20%, Hertz Strengthens Board, Apple Cuts Jobs | NYSE:LLY | Eli Lilly and Co |
08/27/2024 | 6:45AM | PR Newswire (US) | Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity | NYSE:LLY | Eli Lilly and Co |
08/26/2024 | 4:47PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:LLY | Eli Lilly and Co |
08/26/2024 | 4:21PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
08/26/2024 | 8:58AM | IH Market News | IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts | NYSE:LLY | Eli Lilly and Co |
08/23/2024 | 4:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
08/22/2024 | 12:54PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:LLY | Eli Lilly and Co |
08/22/2024 | 10:00AM | PR Newswire (US) | Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference | NYSE:LLY | Eli Lilly and Co |
08/21/2024 | 4:15PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
08/21/2024 | 8:12AM | IH Market News | Walmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest News | NYSE:LLY | Eli Lilly and Co |